10/18/2024

Janusmed sex and gender

Janusmed sex and gender – capecitabine

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Capecitabine

Capecitabine

Class : C

Show all info

Print

Contact us

  1. Xeloda (capecitabine). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-05-27, cited 2019-10-16].

  2. Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol. 1999;44(6):453-60.

  3. Maselli MA, Ignazzi A, Pezzolla F, Scirocco A, Lorusso D, De Ponti F et al. Gender-differences of in vitro colonic motility after chemo- and radiotherapy in humans. BMC Pharmacol Toxicol. 2018;19(1):49.

  4. Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S et al. Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract. 2016;22(3):454-60.

  5. Watanabe A, Yang CC, Cheung WY. Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients. Med Oncol. 2018;35(10):125.

  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-10-29.]

  1. Xeloda (capecitabine). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-05-27, cited 2019-10-16].
  2. Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol. 1999;44(6):453-60.
  3. Maselli MA, Ignazzi A, Pezzolla F, Scirocco A, Lorusso D, De Ponti F et al. Gender-differences of in vitro colonic motility after chemo- and radiotherapy in humans. BMC Pharmacol Toxicol. 2018;19(1):49.
  4. Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S et al. Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract. 2016;22(3):454-60.
  5. Watanabe A, Yang CC, Cheung WY. Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients. Med Oncol. 2018;35(10):125.
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-10-29.]